30 closest matches · ranked by relevance
Measles; Mumps; Rubella · Measles-Mumps-Rubella Vaccine
Primary: Number of Subjects Reporting Fever After MMR (Priorix or M-M-R II/M-M-R VaxPro [Lot 1 or Lot 2]) Vaccination — 47; 17; 205; 95 Participants
Respiratory Syncytial Virus Infection · Premature Birth · Bronchopulmonary Dysplasia
Primary: Frequency of Adverse Events — 41 participants
Sepsis Syndrome
Primary: Induction of MDSCs — 0.19; 0.11 fold change compared to baseline
Measles Antibody Seroconversion · Rubella Antibody Seroconversion · Rotavirus Geometric Mean Titer (GMT)
Primary: Percentage/Number of Subjects With Seroprotection for Measles Virus Serum Neutralization Antibodies — 171; 173; 56; 60 Participants
Varicella · Rubella · Mumps
Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Antibodies — 149; 153; 72; 149 Participants
Hepatitis A · Measles · Mumps
Primary: Participants With 1 or More Serious Vaccine-Related Adverse Experiences — 0; 1 participants
Japanese Encephalitis
Primary: Number and Percentage of Subjects With Demonstrated Seropositivity for Japanese Encephalitis (JE) Neutralizing Antibodies — 14; 243; 233; 24 Participants
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions — 7 participants
Measles-Mumps-Rubella
Primary: Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value — 697; 249; 736; 281 Participants
Rubella · Mumps · Measles
Primary: Number of Subjects With Anti-measles Virus Antibody Concentration Equal to or Above the Cut-off-value. — 245; 236; 236; 248 Subjects
Rubella · Mumps · Measles
Primary: Anti-measles Virus Antibody Concentrations. — 1795.6; 1783.3 mIU/mL
Measles/Rubella
Primary: Number of Participants With Serious Adverse Drug Reactions (ADRs) — 2 Participants
Vaccination
Primary: ELISA Seropositivity Rate — 40.9; 100.0 percentage of subjects
Respiratory Syncytial Virus (RSV)
Primary: Percentage of Participants With RSV Hospitalization — 0.0 percentage of participants
Varicella · Rubella · Mumps
Primary: Number of Subjects With Seroresponse for Antibodies to Varicella Virus (VZV) — 355; 440; 301 subjects
Non-target Heterologous Effects of Vaccines · Vaccine Interactions
Primary: Effect on Interferon (IFN)-Gamma : Interleukin (IL)-4 Ratio in Plasma — 1.48; 1.44; 0.46 ratio of cytokines in pg/mL
Measles · Rubella · Rubella Syndrome, Congenital
Primary: Percent of Infants Who Were Seropositive After Immunization at 6 Months (Assessed at 9-month Visit) — 94; 94 percentage of infants
Hepatitis A Virus
Primary: Antibody Response to Hepatitis A - Participants With a Serological Response — 182; 158 Participants — p=<0.001
Varicella · Chickenpox Vaccines
Primary: Phase A: Number of Subjects With Confirmed Varicella Case — 37; 243; 201 Participants — p=<0.0001
Rabies
Primary: Number of Participants With a Boostability of the Rabies Antibodies After Booster Vaccination — 185; 183 Participants
Respiratory Syncytial Virus Infection
Primary: Number of Hospital Admissions by Respiratory Syncytial Virus Infection — 2 participants
Respiratory Syncytial Virus Infections
Primary: Incidence of RSV Hospitalization (Includes Deaths by RSV) — 62; 46 Participants
Measles · Varicella · Mumps
Primary: Number of Subjects Seroconverted for Measles, Mumps, Rubella and Varicella Antibodies Greater Than or Equal to (≥) the Cut-off Value. — 312; 157; 279; 142 Participants
Japanese Encephalitis · Measles · Mumps
Primary: Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or…
Measles · Mumps · Rubella
Primary: Antibody Response to Varicella for Subjects Who Had Previously Received M-M-R II + VARIVAX - Geometric Mean Titer — 322.2; 209.3 gpELISA units/mL
Measles · Mumps · Rubella
Primary: Percentage of Participants in Arm 2 and Arm 3 Meeting Antibody Immunogenicity Response Criteria Following ProQuad® Dose 2 — 98.0; 98.8; 99.5; 99.5 Percentage of…
Encephalitis, Japanese B
Primary: Percentage of Participants With Seroprotection for Measles 4 Weeks After Vaccination — 1.1; 0.0; 0.0; 88.6 percentage of participants
Prophylaxis for the Measles Infection
Primary: Incidence of Solicited Reactions — 0; 0; 0 participants
Measles; Mumps; Rubella; Chickenpox · Measles
Primary: GMC of Anti-measles Antibodies at Day 43 — 801; 788; 728; 682 mIU/mL
Healthy
Primary: Area Under the Viral Load-Time Curve (VL-AUC) of Respiratory Syncytial Virus (RSV) by Quantitative Reverse Transcriptase-Polymerase Chain Reaction (qRT-PCR) — 0; 236…